Literature DB >> 30317433

Common clinical markers predict end-stage renal disease in children with obstructive uropathy.

Daryl J McLeod1,2, Christina B Ching3,4, Yuri V Sebastião5, Jason H Greenberg6, Susan L Furth7, Kirk M McHugh4,8, Brian Becknell4,9.   

Abstract

BACKGROUND: Obstructive uropathy (OU) is a common cause of end-stage renal disease (ESRD) in children. Children who escape the newborn period with mild-to-moderate chronic kidney disease (CKD) continue to be at increased risk. The predictive ability of clinically available markers throughout childhood is poorly defined.
METHODS: Patients with OU were identified in the Chronic Kidney Disease in Children Study. The primary outcome of interest was renal replacement therapy (RRT) (cases). Controls were age matched and defined as patients within the OU cohort who did not require RRT during study follow-up.
RESULTS: In total, 27 cases and 41 age-matched controls were identified. Median age at baseline and age at outcome measurement were 10 vs. 16 years, respectively. First available glomerular filtration rate (GFR) (36.9 vs. 53.5 mL/min per 1.73 m2), urine protein/creatinine (Cr) (0.40 vs. 0.22 mg/mg) and microalbumin/Cr (0.58 vs. 0.03 mg/mg), and serum CO2 (20 vs. 22 mmol/L) and hemoglobin (12.4 vs. 13.2 g/dL) differed significantly between cases and controls, respectively. GFR declined 3.07 mL/min per 1.73 m2/year faster in cases compared to that in controls (p < 0.0001). Urine protein/Cr and microalbumin/Cr increased by 0.16 and 0.11 per year more in cases compared to those in controls, respectively (p ≤ 0.001 for both). Serum phosphate increased by 0.11 mg/dL and serum albumin and hemoglobin decreased by 0.04 (g/dL) and 0.14 (g/dL) per year more for cases compared to those for controls, respectively (p < 0.05 for all).
CONCLUSIONS: Age-specific baseline and longitudinal measures of readily available clinical measures predict progression to ESRD in children with mild-to-moderate CKD from OU.

Entities:  

Keywords:  CKiD; Chronic kidney disease; End-stage renal disease; Obstruction; Prediction; Uropathy

Mesh:

Substances:

Year:  2018        PMID: 30317433      PMCID: PMC6500428          DOI: 10.1007/s00467-018-4107-z

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  21 in total

1.  Posterior urethral valves: multivariate analysis of factors affecting the final renal outcome.

Authors:  Osama M Sarhan; Alaa A El-Ghoneimi; Tamer E Helmy; Mohamed S Dawaba; Ahmad M Ghali; El-Houssiny I Ibrahiem
Journal:  J Urol       Date:  2011-04-28       Impact factor: 7.450

2.  Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury.

Authors:  P Ruggenenti; A Perna; G Gherardi; R Benini; G Remuzzi
Journal:  Am J Kidney Dis       Date:  2000-06       Impact factor: 8.860

3.  Progression of chronic renal failure in children with dysplastic kidneys.

Authors:  Claudia González Celedón; María Bitsori; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2007-03-23       Impact factor: 3.714

4.  Renal outcome in patients with congenital anomalies of the kidney and urinary tract.

Authors:  Simone Sanna-Cherchi; Pietro Ravani; Valentina Corbani; Stefano Parodi; Riccardo Haupt; Giorgio Piaggio; Maria L Degli Innocenti; Danio Somenzi; Antonella Trivelli; Gianluca Caridi; Claudia Izzi; Francesco Scolari; Girolamo Mattioli; Landino Allegri; Gian Marco Ghiggeri
Journal:  Kidney Int       Date:  2009-06-17       Impact factor: 10.612

5.  Changing trends in pediatric transplantation: 2001 Annual Report of the North American Pediatric Renal Transplant Cooperative Study.

Authors:  Mark R Benfield; Ruth A McDonald; Sharon Bartosh; P L Ho; William Harmon
Journal:  Pediatr Transplant       Date:  2003-08

6.  Posterior urethral valves: prognostic factors.

Authors:  P Lopez Pereira; L Espinosa; M J Martinez Urrutina; R Lobato; M Navarro; E Jaureguizar
Journal:  BJU Int       Date:  2003-05       Impact factor: 5.588

7.  Obstructive nephropathy in the rat: possible roles for the renin-angiotensin system, prostaglandins, and thromboxanes in postobstructive renal function.

Authors:  W E Yarger; D D Schocken; R H Harris
Journal:  J Clin Invest       Date:  1980-02       Impact factor: 14.808

8.  Design and methods of the Chronic Kidney Disease in Children (CKiD) prospective cohort study.

Authors:  Susan L Furth; Stephen R Cole; Marva Moxey-Mims; Frederick Kaskel; Robert Mak; George Schwartz; Craig Wong; Alvaro Muñoz; Bradley A Warady
Journal:  Clin J Am Soc Nephrol       Date:  2006-07-19       Impact factor: 8.237

9.  Timing and outcome of renal replacement therapy in patients with congenital malformations of the kidney and urinary tract.

Authors:  Elke Wühl; Karlijn J van Stralen; Enrico Verrina; Anna Bjerre; Christoph Wanner; James Goya Heaf; Oscar Zurriaga; Andries Hoitsma; Patrick Niaudet; Runolfur Palsson; Pietro Ravani; Kitty J Jager; Franz Schaefer
Journal:  Clin J Am Soc Nephrol       Date:  2012-10-18       Impact factor: 8.237

10.  Posterior urethral valves: Persistent renin angiotensin system activation after valve ablation and role of pre-emptive therapy with angiotensin converting enzyme-inhibitors on renal recovery.

Authors:  Minu Bajpai; Pradeep K Chaturvedi; Chandra S Bal; Meher C Sharma; Mani Kalaivani
Journal:  J Indian Assoc Pediatr Surg       Date:  2013-04
View more
  2 in total

1.  Longitudinal kidney injury biomarker trajectories in children with obstructive uropathy.

Authors:  Daryl J McLeod; Yuri V Sebastião; Christina B Ching; Jason H Greenberg; Susan L Furth; Brian Becknell
Journal:  Pediatr Nephrol       Date:  2020-05-22       Impact factor: 3.714

2.  Evaluation of polyuria and polydipsia along with other established prognostic factors in posterior urethral valves for progression to kidney failure: experience from a developing country.

Authors:  Naveen Kumar; Priyank Yadav; Shrey Jain; Abhay Kumar G; Vinay N Kaushik; M S Ansari
Journal:  Pediatr Nephrol       Date:  2021-01-07       Impact factor: 3.714

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.